Clinical Trials Browser

Phase 1/2 × Lymphoma × Vemurafenib × Clear all

NCT03013491 2025-06-17

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

Phase 1/2 Terminated

196 enrolled 28 charts

Diabetes Mellitus, Insulin-Dependent, 12, Lymphoma, Neoplasms